Mercato chiuso -
Altri mercati azionari
|
Variaz. 5gg | Var. 1 gen. | ||
71,6 CHF | -0,69% | +0,28% | +40,67% |
Attività
Numero di dipendenti: 319
Vendite per attività
CHF in Milioni | 2021 | Peso | 2022 | Peso | Delta |
---|---|---|---|---|---|
Own Products
52,0
%
| 43 | 60,6 % | 53 | 52,0 % | +25,05% |
Licence Fees, Up-front Fees and Milestones
23,8
%
| 6 | 8,5 % | 24 | 23,8 % | +310,51% |
Generic Products, Specialty Drugs and Related Services
12,9
%
| 14 | 19,4 % | 13 | 12,9 % | -3,41% |
Royalties
9,7
%
| 6 | 8,6 % | 10 | 9,7 % | +63,17% |
Other
1,6
%
| 2 | 2,9 % | 2 | 1,6 % | -17,40% |
Vendite per regione
CHF in Milioni | 2021 | Peso | 2022 | Peso | Delta |
---|---|---|---|---|---|
Italy
100,0
%
| 70 | 100,0 % | 102 | 100,0 % | +45,72% |
Dirigenti
Dirigenti | Titolo | Età | Da |
---|---|---|---|
Chief Executive Officer | 61 | 01/01/06 | |
Niall Donnelly
DFI | Director of Finance/CFO | 52 | 01/06/16 |
Chief Tech/Sci/R&D Officer | 54 | - | |
Luigi Longo
CTO | Chief Tech/Sci/R&D Officer | 45 | 01/06/05 |
Davide Malavasi
CTO | Chief Tech/Sci/R&D Officer | 51 | 01/09/11 |
Marco Lecchi
COO | Chief Operating Officer | 60 | 01/01/01 |
Hazel Winchester
IRC | Investor Relations Contact | 53 | 10/01/22 |
Nhan Ngo Dinh
PRN | Corporate Officer/Principal | 45 | - |
Biagio Viganò
HRO | Human Resources Officer | 50 | - |
Diana Harbort
PRN | Corporate Officer/Principal | 57 | 01/01/22 |
Amministratori
Amministratori | Titolo | Età | Da |
---|---|---|---|
David W Maris
BRD | Director/Board Member | 57 | 28/05/21 |
Founder | 69 | 01/01/97 | |
Director/Board Member | 64 | 01/01/06 | |
Director/Board Member | 69 | 01/04/12 | |
Director/Board Member | 65 | 01/03/16 | |
Chief Executive Officer | 61 | 01/01/06 |
Classe di azioni
Voto | Quantità | Flottante | Autocontrollo | Flottante totale | |
---|---|---|---|---|---|
Azione A | 1 | 17 543 522 | 7 805 026 ( 44,49 %) | 1 490 681 ( 8,497 %) | 44,49 % |
Partecipazioni
Nome | Azioni | % | Valorizzazione |
---|---|---|---|
1 283 390 | 7.32% | 101 593 999 $ |
Coordinate società
Cosmo Pharmaceuticals NV
Riverside II Sir John Rogerson's Quay
2, Dublin
+353 1 817 0370
http://www.cosmopharma.comSocietà del gruppo
Nome | Categoria e settore |
---|---|
Pharmaceuticals: Major
| |
Cosmo Technologies Ltd.
Cosmo Technologies Ltd. Pharmaceuticals: MajorHealth Technology Part of Cosmo Pharmaceuticals NV, Cosmo Technologies Ltd. is an Irish pharmaceutical company that manufactures and distributes pharmaceutical products. The private company is based in Dublin, Ireland. Cosmo Technologies was acquired by Salix Pharmaceuticals Ltd. from Cosmo Pharmaceuticals SA. |
Pharmaceuticals: Major
|
Granell Strategic Investment Fund Ltd.
|
Investment Managers
|
Settore
Vendite per attività
Revisioni EPS
Variaz. 1 gen. | Capi. | |
---|---|---|
+40,67% | 1,26 Mrd | |
+25,83% | 661 Mrd | |
+27,00% | 566 Mrd | |
-6,76% | 352 Mrd | |
+20,34% | 332 Mrd | |
+3,00% | 283 Mrd | |
+13,09% | 231 Mrd | |
+5,46% | 200 Mrd | |
-9,61% | 195 Mrd | |
-6,26% | 145 Mrd |
- Borsa valori
- Azioni
- Azione COPN
- Società Cosmo Pharmaceuticals N.V.